stockrowWhat it does
Immunovant is a clinical-stage immunology company developing treatments for autoimmune diseases, in which the immune system attacks the body’s own tissues. It has never generated revenue and does not yet sell a medicine. Its chief executive officer is Eric Venker.
The company is focused on IMVT-1402, also called imeroprubart, an investigational antibody designed for diseases driven by harmful immunoglobulin G, or IgG, antibodies. A protein called FcRn normally helps protect IgG antibodies from being broken down. IMVT-1402 blocks FcRn, allowing more of those antibodies to be degraded rather than returned to circulation.
Immunovant is studying the drug in Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Sjögren’s disease and cutaneous lupus erythematosus. These conditions affect different parts of the body, including the thyroid, joints, nerves and skin. The company is using an autoinjector intended for commercial use in its IMVT-1402 studies.
In April 2026, two Phase 3 studies of its earlier antibody, batoclimab, in thyroid eye disease failed to meet their primary endpoints. Immunovant then discontinued batoclimab development across all indications and focused on IMVT-1402, while continuing to use clinical and operational experience from the earlier program.
How it makes money
Immunovant has never generated revenue. It does not expect product revenue unless and until it completes development and obtains regulatory approval for IMVT-1402 or a future candidate. There is therefore no established product-sales or recurring-revenue stream.
For the year ended March 31, 2026, the company had a net loss of $505.6 million; it had cash and cash equivalents of $902.1 million as of March 31, 2026.
The intended route to product revenue is to develop a medicine for a specific disease, demonstrate its safety and effectiveness in clinical trials, obtain marketing approval and then commercialize it. Immunovant is conducting potentially registrational trials in Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease. It is also conducting a proof-of-concept trial in cutaneous lupus erythematosus. The company expects to build sales, marketing and distribution capabilities if it obtains approval.
For now, Immunovant finances its operations primarily through equity offerings. It expects future cash needs to be met through a combination of equity offerings, debt financing and potential collaboration, license or development agreements until it can generate substantial product revenue, if ever. Such agreements could require the company to give third parties rights to future revenue, research programs or candidates.
Immunovant expects its cash and cash equivalents as of March 31, 2026 to fund announced indications through the potential commercial launch of IMVT-1402 in Graves’ disease. It also says those funds will not be sufficient to complete development and, if approved, commercially launch the drug in every indication it is currently evaluating.
Customers and how it sells
Immunovant’s prospective patients are people with IgG-driven autoimmune diseases, including patients whose disease remains active despite existing treatment. It has not generated revenue, so it does not have a product-sales customer base or reported customer concentration.
The company’s studies target distinct patient groups. Its Graves’ disease trials enroll adults who remain hyperthyroid despite treatment with an antithyroid drug. Its difficult-to-treat rheumatoid arthritis study focuses on patients with a particular autoantibody who have had inadequate responses to prior advanced therapies. Its Sjögren’s disease study evaluates adults with moderate to severe systemic primary disease.
Immunovant cites estimates that over four million patients in the United States and Europe could benefit from anti-FcRn treatments across more than 20 indications publicly announced for research and development by multiple companies. This estimate covers the drug class and multiple companies’ programs, not just Immunovant’s candidates.
The company plans to establish sales, marketing and distribution infrastructure if it obtains approval. Its workforce was primarily in the U.S. as of March 31, 2026. It and its contractors must meet the requirements of the authorities in each country where it conducts studies or seeks approval.
Suppliers and costs
Immunovant’s primary use of cash is to fund clinical trials, clinical development and manufacturing. It enters agreements with contract research organizations for trials and with vendors for nonclinical studies, manufacturing and other services and products. Most of these agreements are cancellable, subject to remaining obligations under binding purchase orders and, in some cases, early-termination fees.
IMVT-1402 studies use the YpsoMate autoinjector developed by Ypsomed AG. Immunovant developed IMVT-1402 and batoclimab through a research program with HanAll. It expects milestones under agreements with third parties, including the HanAll agreement, to require substantial payments.
The company expects to increase manufacturing of IMVT-1402 drug substance and drug product for trials and to scale up external manufacturing if it commercializes an approved candidate. As of March 31, 2026, it had 315 full-time permanent employees, with approximately 85% engaged in research and development activities. It expects significant expenses to continue for at least the next several years.
Competitive position
Immunovant expects competition from companies developing other FcRn inhibitors and from treatments that work through different biological mechanisms. Argenx’s efgartigimod, UCB’s rozanolixizumab and Johnson & Johnson’s nipocalimab have received FDA approvals for forms of myasthenia gravis. Argenx’s VYVGART Hytrulo is also approved for chronic inflammatory demyelinating polyneuropathy.
In Graves’ disease, Immunovant identifies several drugs in development, including programs from Argenx, Viridian Therapeutics, Biohaven and Sanofi. In cutaneous lupus erythematosus, it identifies development programs from Biogen, AstraZeneca and Merck. Nipocalimab and efgartigimod are also in Phase 3 trials for Sjögren’s disease.
Immunovant believes IMVT-1402 could differentiate itself through the depth of IgG reduction, its safety profile and a self-administered autoinjector. In a Phase 1 trial in healthy adults, the drug produced dose-dependent IgG reductions, with no or minimal reductions in albumin and no or minimal increases in LDL cholesterol across evaluated doses. The company says competitors can also have greater resources and more experience gaining approvals and commercializing drugs.
Our reading: IMVT-1402’s clinical profile and delivery device are possible sources of differentiation, but their strength as a competitive moat remains unproven without approval and commercial use. Our reading: Existing approved FcRn therapies and competing development programs limit the protection Immunovant can derive from targeting the mechanism alone.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Argenx SE | FcRn therapies for myasthenia gravis, CIDP and other indications | High |
| Johnson & Johnson | FcRn therapies for myasthenia gravis and other autoimmune diseases | High |
| UCB | FcRn therapy for generalized myasthenia gravis | High |
| Viridian Therapeutics | FcRn inhibitors and a Graves’ disease candidate | Medium |
| AstraZeneca | Approved myasthenia gravis therapy and lupus development | High |
| Sanofi | CIDP and Graves’ disease drug development | Medium |
| Biogen | Cutaneous lupus erythematosus drug development | Medium |
| Merck | Cutaneous lupus erythematosus drug development | Medium |
Growth opportunities
Immunovant’s growth plans center on developing IMVT-1402 across autoimmune diseases rather than relying on a single indication. It is prioritizing its six ongoing programs and plans to evaluate additional indications based on medical need, potential benefit, patient population and commercial potential.
The company expects top-line results from its two potentially registrational Graves’ disease trials and its myasthenia gravis trial in calendar year 2027. It expects results from its chronic inflammatory demyelinating polyneuropathy and Sjögren’s disease trials in calendar year 2028. It also expects top-line results from its cutaneous lupus erythematosus proof-of-concept trial in the second half of calendar year 2026.
In difficult-to-treat rheumatoid arthritis, the first part of the IMVT-1402 study was open-label. At Week 16, the ACR20 response rate was 72.7%; the study’s primary endpoint is assessed in a subsequent randomized period. Immunovant expects further updates in the second half of calendar year 2026 and says the randomized-period results may inform whether the study can serve as a pivotal study.
The company estimates approximately 330,000 U.S. Graves’ patients have relapsed on antithyroid drugs and opted not to pursue ablation. It also estimates approximately 90,000 U.S. primary Sjögren’s patients have moderate-to-severe disease with anti-Ro/SSA antibodies. These are estimates of patient populations, not forecasts of Immunovant’s sales.
Structural risks
- Clinical results and approval: Trial results may not meet regulators’ requirements for statistical or clinical significance. Regulators may disagree with trial design or require additional studies before approval.
- Safety: Unexpected adverse events can delay trials or lead to clinical holds. If an approved product causes serious or unexpected side effects, regulators could restrict its use or withdraw approval.
- Funding: Immunovant expects continued net losses and has no committed external source of funds. If it cannot raise sufficient capital, it may have to delay, reduce or terminate development or grant rights it would otherwise retain.
- Competition: Other companies have approved therapies or candidates in development. Competing trials can also reduce the number of patients available for Immunovant’s studies.
- Manufacturing and contractors: Trials can be delayed if sufficient quantities of candidate drugs or placebo cannot be manufactured or released to quality standards. Regulators may identify deficiencies at third-party manufacturing facilities.
- Commercial adoption: If a candidate is approved, its success will depend on factors including efficacy, safety, dosing convenience, price, coverage and reimbursement. Immunovant says competitors can have more experience commercializing approved drugs.
Bottom line
Our reading
Immunovant is a clinical-stage business whose future product revenue depends on turning IMVT-1402 trials into approvals and sales across autoimmune diseases. Its development plans span several conditions, but the discontinuation of batoclimab leaves the company focused on one candidate. Cash and equity financing support the current program, while trial outcomes, competition and the cost of developing and launching additional indications remain central exposures.